Updated: Bristol Myers touts LAG-3 strategy in lung cancer, but data caveats dampen excitement

Ayisha Sharma

News Reporter

BARCELONA — Bristol Myers Squibb’s LAG-3 approach has shown potential in certain lung cancer patients in a Phase 2 study, but “cherry-picked” analysis comes with its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Bristol Myers touts LAG-3 strategy in lung cancer, but data caveats dampen excitement

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

All of 23andMe's independent board members resign over disagreements with CEO

Bad trip: How culture conflict and a need for cash nearly broke Lykos

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers

Breaking down silos with a new quantitative approach to drug development

Up­dat­ed: Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer, but da­ta caveats damp­en ex­cite­ment

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Updated: Bristol Myers touts LAG-3 strategy in lung cancer, but data caveats dampen excitement